DBVT News and Press, DBV Technologies S.A. From 10/09/19

DBV Technologies Announces Pricing of $125 million ( € 114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: D...

Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position DBV Technologies (the “Company”) (Euronext: DBV &...

Gainers:  Asure Software (NASDAQ: ASUR ) +22% . SunLink Health Systems (NYSEMKT: SSY ) +10% . AgeX Therapeutics (NYSEMKT: AGE ) +9% . NIO (NYSE: NIO ) +9% . ATIF Holdings (NASDAQ: ATIF ) +8% . Frontier Communications Corporation (NASDAQ: FTR ) +8% . Nordic American Tankers Limit...

According to industry and sector data analysed by GlobalData, Merck's ( MRK ) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myer...

QIAGEN (NYSE: QGEN )  -18%  on reporting preliminary Q3 results. More news on: QIAGEN N.V., Ocugen, Inc., Ambarella, Inc., Stocks on the move, Read more ...

DBV Technologies ( DBVT +2.8% ) says the Food and Drug Administration has accepted the Biologics License Application for its Viaskin peanut immunotherapy for the treatment of peanut-allergic children aged 4-11; shares are halted. More news on: DBV Technologies S.A., Healthcare stocks n...

Montrouge, France, October 4, 2019 DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in...

We haven't covered Aimmune Therapeutics, Inc. ( AIMT ) as much as we should, barring an article comparing Aimmune and its distant competitor DBV Technologies ( DBVT ), where we said that AIMT is probably the better investment. Late last year, after DBVT withdrew its US marketing application ...

Montrouge, France, August 7, 2019 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopha...

Montrouge, France, August 1, 2019 DBV Technologies Reports First Half 2019 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2019 financial results. The inte...